Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
نویسندگان
چکیده
Peripheral T-cell lymphomas (PTCLs) represent an uncommon heterogenous group of neoplasms that make up approximately 10% to 15% of non-Hodgkin lymphomas. PTCL, not otherwise specified (NOS) is the most common form, whose incidence in the United States has been increasing, possibly due to better diagnostic methods. PTCLs represent a rare and aggressive subgroup of NHLs that do not respond favorably to traditional chemotherapies. Since the majority of patients with PTCL experience disease relapse or disease that is refractory to previous agents, the continued development of novel targeted therapies is critical and necessary in order to improve outcomes in this aggressive, difficult to treat, heterogeneous group of malignant disorders.
منابع مشابه
New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of rare malignancies that with the exception of anaplastic lymphoma kinase expressing anaplastic large cell lymphoma, share a poor outcome after standard (eg, anthracycline-based) chemotherapy. Most patients are either refractory to initial therapy or eventually relapse. Randomized studies for relapsed/refractory PTCL are not av...
متن کاملLong-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma
Peripheral T/NK-cell lymphomas (PTCL) are rare malignancies with a poor prognosis. Due to the lack of randomised studies, standard therapy has not been established. First-line treatment with anthracycline-based polychemotherapy followed by consolidation with high-dose therapy and autologous stem cell transplant in responding patients has demonstrated good feasibility with low toxicity in prospe...
متن کاملProfile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
The peripheral T-cell lymphomas are a rare and heterogeneous group of mature T-cell lymphomas with limited available therapies. The outcome of frontline chemotherapy regimens has been disappointing, with a long-term survival of only 20%-30%. There is an urgent need to optimize induction therapy by incorporating novel agents that target the dysregulated pathways. Histone deacetylase inhibitors t...
متن کاملFDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
On July 3, 2014, the FDA granted accelerated approval for belinostat (Beleodaq; Spectrum Pharmaceuticals, Inc.), a histone deacetylase inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). A single-arm, open-label, multicenter, international trial in the indicated patient population was submitted in support of the application. Belinostat was adm...
متن کاملX. Challenges and future directions in peripheral T-cell lymphoma.
Treatment paradigms for peripheral T-cell lymphomas (PTCLs) have been modelled after B-cell lymphomas; however, cyclophosphamide,doxorubicin, vincristine, and prednisone (CHOP)-(like) chemotherapy remains largely ineffective. The clear exception is anaplastic lymphoma kinase positive anaplastic large cell lymphoma (ALCL) (ALK+ALCL), which has high cure rates with CHOP. A subset of ALK-negative ...
متن کامل